Statin efficacy in the treatment of hepatitis C genotype I

Journal of Research in Medical Sciences

Volumn 19, Issue SPEC. ISSUE, 2014, Pages

  Shavakhi, Ahmad ^a   Minakari, Mohamad ^a   Bighamian, Afshin ^a   Sadeghian, Sina ^a   Shavakhi, Sara ^b   Khamisi, Naser ^a   Khodadustan, Mahsa ^a   Talebi, Majid ^a   Ataei, Behrooz ^b  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis c; Hyperlipidemia; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

EID: 84900302330     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
2. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
3. Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis. Antiviral Res 2013;98:373-9.
4. Vere CC, Streba CT, Streba L, Rogoveanu I. Statins in the treatment of hepatitis C. Hepat Mon 2012;12:369-71.
5. Blanchet M, Seidah NG, Labonté P. SKI-1/S1P inhibition: A promising surrogate to statins to block hepatitis C virus replication. Antiviral Res 2012;95:159-66.
6. Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007;132:311-20.
7. Ikeda M, Kato N. Life style-related diseases of the digestive system: Cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145-50.
8. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011;55:4569-74.
9. Andrus MR, East J. Use of statins in patients with chronic hepatitis C. South Med J 2010;103:1018-22.
10. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: A distinct syndrome? Intern Emerg Med 2008;3:99-108.
11. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
12. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic eff ect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
13. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90.
14. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fi brosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
15. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: Hepatitis C virus-associated steatosis - Pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005;22 Suppl 2:52-5.
16. Lecube A, Hernández C, Simó R, Esteban JI, Genescà J. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 2007;102:2189-95.
17. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. Hepatology 2007;45:895-8.
18. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:1383-9.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
20. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fi brosis progression [corrected]. Gastroenterology 2003;125:1695-704.
21. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004;24:399-413.
22. Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, Gounon P, et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001;75:8240-50.
23. Forde KA, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009;15:5020-7
24. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profi les of statins and their potential for combination therapy with interferon. Hepatology 2006;44:117-25.
25. Fried MW, Shiff man ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
26. Vere CC, Streba CT, Streba L, Rogoveanu I. Statins in the Treatment of Hepatitis C. Hepatitis Monthly 2012;12:369-71.
27. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specifi c mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-81.
28. Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iran Red Crescent Med J 2012;14:466-9.
29. Alavian SM, Behnava B, Tabatabaei SV. The comparative effi cacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: A meta-analysis. Hepat Mon 2010;10:121-31.